Maternal safety and fetal outcomes associated with the use of pharmacological agents in the management of pre-eclampsia

Authors

  • Grasiele Andrade Pires Author
  • Laura Gabrielly Cintra Author
  • Luan Mateus Lopes De Sousa Author
  • Sarah Carvalho Santos Barreto Author
  • Veronica Souza Bolsi Author
  • Luciano De Oliveira Souza Tourinho Author

DOI:

https://doi.org/10.69849/rjmedf56

Keywords:

Prenatal care, Pregnant women, Hypertensive disorders

Abstract

Introduction: Preeclampsia is one of the main hypertensive complications of pregnancy and represents an important public health problem due to the risks it poses to both the mother and the fetus. The condition usually manifests after the 20th week of gestation and is characterized by increased blood pressure, which may be associated with proteinuria and alterations in different maternal organs. In this context, the use of medications in the management of preeclampsia becomes essential for controlling maternal blood pressure and preventing severe complications, making it fundamental to evaluate maternal safety and the possible effects of these drugs on fetal development.Objectives: To analyze maternal safety and the possible fetal repercussions associated with the use of drugs in the management of preeclampsia. As specific objectives, the study seeks to discuss the main medications used in the treatment of the condition, evaluate their effects in reducing maternal complications, and analyze their possible implications for fetal outcomes.Methodology: This study is an integrative literature review carried out with the aim of gathering and analyzing scientific evidence on the use of drugs in the management of preeclampsia and their maternal and fetal repercussions. The search was conducted in the Medical Literature Analysis and Retrieval System Online (Medline) and the Latin American and Caribbean Health Sciences Literature (LILACS) databases. Descriptors from the MeSH and DeCS vocabularies were used and combined using Boolean operators. Articles published between 2020 and 2026, available in full text, in Portuguese and English, and addressing the proposed theme were included.Results and discussion: The analyzed studies showed that preeclampsia affects approximately 5% to 8% of pregnancies and is associated with important maternal and perinatal complications. Proper clinical management, including blood pressure monitoring and the use of medications such as antihypertensive drugs and magnesium sulfate, has been shown to significantly contribute to the prevention of severe complications, such as eclampsia and HELLP syndrome.Conclusion: It is concluded that the proper management of preeclampsia, especially through the safe use of medications and rigorous clinical monitoring, plays a fundamental role in reducing maternal and fetal complications.

References

ALMEIDA, A.R et al. Manejo da pré -eclâmpsia na clínica médica. Contribuciones a las Ciencias Sociales, v. 18, n. 3, p. 12, 2025.

AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG) –Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol, v. 135, n. 6, p. e237-e260, 2024.

ARAUJO, R.B et al. Pré-eclâmpsia: Desafios e Impactos da Profilaxia na Saúde Materno-Infantil. Brazilian Journal of Implantology and Health Sciences, v. 7, n. 2, p. 2526-2548, 2025.

CARDOSO, A.M et al. Pré-eclâmpsia: uma revisão bibliográfica dos fatores de risco e estratégias preventivas. RECIMA21-Revista Científica Multidisciplinar-ISSN 2675-6218, v. 5, n. 3, p. e534954-e534954, 2024.

FERNANDES, J.P et al. Complicações hipertensivas na gravidez: a Síndrome HELLP e sua correlação clínica com a Pré-Eclâmpsia. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 8, p. 1991-2018, 2024.

GALINDO, M.C et al. Pré-Eclâmpsia: Estratégias de intervenção e seus efeitos na saúde materna a curto e longo prazo. Journal of Medical and Biosciences Research, v. 3, n. 1, p. 278–283-278–283, 2026.

GOMES, M.C et al. Linhas de cuidado em enfermagem à gestante com pré-eclâmpsia. Revista Políticas Públicas & Cidades, v. 13, n. 2, p. e979-e979, 2024.

GONÇALVES, A.W et al. Evidências do tratamento e da profilaxia da pré-eclâmpsia na gestação. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 10, p. 402-422,

2024.

MARQUES, A.B et al. Manejo da pré-eclâmpsia em gestação acima de 36 semanas. Caminhos da Clínica, n. 3, 2024.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Hypertension in pregnancy: diagnosis and management. NICE guideline (NG133). London: NICE, 2022.

ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS) – diretrizes gerais sobre prevenção e tratamento da pré-eclâmpsia e eclâmpsia. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO, 2023

PRETTI, M.A et al. A influência do diagnóstico precoce da pré-eclâmpsia na mortalidade materna e na fetal. Brazilian Journal of Implantology and Health Sciences, v. 5, n. 5, p. 6583-6591, 2023.

SALGADO, A.L et al. Pré-eclâmpsia e risco cardiovascular de longo prazo em mulheres: Manifestações clínicas e abordagens de tratamento. Revista Ibero-Americana de Humanidades, Ciências e Educação, v. 10, n. 7, p. 525-534, 2024.

SANTOS, F.M et al. Manejo da pré-eclâmpsia pós-parto: Estratégias e tratamentos eficazes. Periódicos Brasil. Pesquisa Científica, v. 3, n. 2, p. 1634-1643, 2024.

SILVA, Y.P et al. Pré-eclâmpsia e suas modalidades de tratamento na gestação. Brazilian Journal of Implantology and Health Sciences, v. 7, n. 10, p. 448-460, 2025.

Published

2026-04-25

How to Cite

Pires, G. A., Cintra, L. G. ., Sousa, L. M. L. D., Barreto, S. C. S. ., Bolsi, V. S., & Tourinho, L. D. O. S. (2026). Maternal safety and fetal outcomes associated with the use of pharmacological agents in the management of pre-eclampsia. Revista Ft, 30(157), 01-13. https://doi.org/10.69849/rjmedf56